Suvadronabinol

It's only fair to share...

Suvadronabinol

CAS 1225194-84-2

MF C30H43NO6 MW513.7 g/mol

4-{[(2S)-3-methyl-1-oxo-1-{[(6aR,10aR)-6,6,9-trimethyl-3-pentyl6a,7,8,10a-tetrahydro-6H-dibenzo[b,d]pyran-1-yl]oxy}butan-2-yl]amino}-4-oxobutanoic acid

3-{[(2S)-1-{[(6aR,10aR)-6,6,9-trimethyl-3-pentyl-6H,6aH,7H,8H,10aH-benzo[c]isochromen-1-yl]oxy}-3-methyl-1-oxobutan-2-yl]carbamoyl}propanoic acid

4-{[(2S)-3-methyl-1-oxo-1-{[(6aR,10aR)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6H-dibenzo[b,d]pyran-1-yl]oxy}butan-2-yl]amino}-4-oxobutanoic acid
cannabinoid receptor agonist, DB 21741, XV9S3R9XJC

Suvadronabinol (DB21741) is a potent, synthetic small-molecule cannabinoid receptor type 1 (CB1) agonist, initially developed for therapeutic potential in areas like appetite stimulation, pain, or weight management, acting similarly to cannabis compounds but with specific design, currently in preclinical research stages, noted for its high selectivity and potency.

Key Characteristics:

Type: Small Molecule Drug.
Mechanism: A highly selective agonist for the cannabinoid receptor type 1 (CB1).
Development: Originally developed by Elsohly Laboratories, it’s in preclinical R&D, with status as an experimental compound.
Molecular Weight: Approximately 513.31 Da.
CAS Number: 1225194-84-2.

Potential Applications (Research Areas):

Appetite Stimulation & Weight Loss: Similar to dronabinol, it targets pathways involved in metabolism and appetite.
Pain Management: As a cannabinoid, it interacts with the endocannabinoid system, which plays a role in pain perception.

Status:

It’s an investigational compound, meaning it’s still under study and not yet approved for medical use.

In essence, Suvadronabinol is a targeted synthetic cannabinoid designed to interact with the body’s CB1 receptors, showing promise in preclinical research for conditions where cannabinoid effects are desired, but it’s not a widely available or established medicine.

SYN

SYN

US20150045282

SYN

WO2010051541

https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2010051541&_cid=P22-MIXZ0J-96045-1

Example 10: Preparation of THC-valinate-hemisuccinate (15):

Compound 15 was also prepared using scheme II, where the starting material was compound 6 (THC-valinate). Product 15 was purified using column chromatography (>85% yield) and confirmed by mass spectroscopy in the positive ionization mode (M+NlV = 531) (Fig 17). The structure of product 15 was also confirmed by spectral analysis ¹H-NMR and ¹³C-NMR (see Fig 18 for ¹³C-NMR assignments).

Spectral analysis of Δ⁹-THC prodrugs prepared above: Identity and purity of the synthesized prodrugs was established by spectral means including ¹H-NMR, ¹³C-NMR and 2D-NMR such as COSY, HMQC, HMBC, as well as other spectroscopic means (IR₁ UV and MS). The synthetic protocols outlined above yielded prodrugs with ≥95% purity.